FDA widens approval of Vertex’s CRISPR medicine to treat beta thalassemia

The Food and Drug Administration on Tuesday approved Vertex Pharmaceuticals’ CRISPR-based medicine Casgevy for the inherited blood condition beta thalassemia, expanding its use six weeks after issuing a landmark clearance in sickle cell disease.